153 related articles for article (PubMed ID: 38054015)
1. Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Li D; Yan J; Li K; Yang Q; Bian L; Lin B; Liu X; Xi Z
PeerJ; 2023; 11():e16426. PubMed ID: 38054015
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
3. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic Shotgun Proteomic Points to Key Proteins and Pathways in Temozolomide-Resistant Glioblastoma Multiforme.
Teraiya M; Krokhin O; Chen VC; Perreault H
J Proteome Res; 2024 Jan; 23(1):465-482. PubMed ID: 38147655
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
6. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Nadkarni A; Shrivastav M; Mladek AC; Schwingler PM; Grogan PT; Chen J; Sarkaria JN
J Neurooncol; 2012 Dec; 110(3):349-57. PubMed ID: 23054561
[TBL] [Abstract][Full Text] [Related]
7. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
8. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
[TBL] [Abstract][Full Text] [Related]
9. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Wang N; Zhang Q; Ning B; Luo L; Fang Y
Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
11. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
12. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
13. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
14. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
[TBL] [Abstract][Full Text] [Related]
15. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
16. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Si J; Li W; Li X; Cao L; Chen Z; Jiang Z
Cancer Sci; 2021 Sep; 112(9):3491-3506. PubMed ID: 34036683
[TBL] [Abstract][Full Text] [Related]
17. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
20. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]